Printer Friendly

Drug trial helps fight blindness; HEALTH.

A NEW drug which could help prevent sight loss caused by a currently untreatable condition is being trialled for the first time in the UK.

Stargardt's disease, also known as Stargardt's macular dystrophy, affects the area of the retina called the macula and causes a reduction in central vision.

It is the most common form of juvenile macular degeneration and affects around one in 10,000 children who suffer a gradual decline in vision which leads to blindness in adulthood.

Professor Andrew Lotery, from University Hospital Southampton NHS Foundation Trust, is to lead the UK's team in a PS5 million study of the drug remofuscin with colleagues in the Netherlands, Italy, Germany and Norway.

The medication removes the lipid - or fat - deposits, known as lipofuscin, which build up in the back of the eye.

COPYRIGHT 2018 Birmingham Post & Mail Ltd
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Birmingham Mail (England)
Date:Feb 12, 2018
Previous Article:Angry models protest over ban on grid girls; march over decision made by formula 1 and darts.
Next Article:Deprived men dying TEN YEARS before borough's better-off; HEALTH DIVIDE BETWEEN SOLIHULL COMMUNITIES LAID BARE IN REPORT.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters